Plagiarism Policy
Research Integrity & Originality Standards
The EPH - International Journal of Biological & Pharmaceutical Science (IJBPS) is committed to the highest levels of scholarly integrity. To safeguard the credibility of pharmaceutical literature, we maintain strict adherence to ethical publishing practices and ensure that every manuscript contributes unique value to the scientific community through original research and transparent reporting.
1. Categorizing Research Misconduct
We maintain a zero-tolerance policy toward the unauthorized representation of external ideas, data, or language. This includes:
- • Direct & Structural Replication: Reproducing text or experimental frameworks without explicit citation.
- • Insufficient Attribution: Presenting findings from other sources with inadequate or misleading paraphrasing.
- • Text Recycling: Republishing one’s own previously documented research without proper disclosure.
2. Editorial Verification Protocols
Detection & Analysis
We utilize iThenticate and Turnitin to analyze submissions. Editors distinguish between standard scientific terminology and duplication to ensure a nuanced, fair evaluation.
Ethical Enforcement
Suspected violations are investigated using COPE (Committee on Publication Ethics) flowcharts. IJBPS reserves the right to reject or retract work found in breach of these standards.
3. Responsibility of Authorship
Authors bear the ultimate responsibility for the originality of their work. This includes ensuring that all datasets are accurate and that collaborative contributions are properly credited. If Generative AI tools are employed in the drafting process, authors remain fully accountable for the factual precision and uniqueness of the output.
✓
Statement of Originality
By submitting to IJBPS, authors certify that their manuscript is an original contribution that has not been published elsewhere. We align our practices with Crossref Similarity Check guidelines to support a transparent and trustworthy scholarly ecosystem.
